FDA Approves Roche's Giredestrant: The Next Competitive Test in ESR1-Mutated Breast Cancer

The U.S. Food and Drug Administration (FDA) approved Roche's oral selective estrogen receptor degrader (SERD), giredestrant, marketed as Wilserdly, in combination with everolimus for adults with ESR1-mutated, estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer following progression during or after endocrine therapy. In a 207-patient pivotal study, the combination reduced the risk of progression or death by 62%, with median progression-free survival of 10 months versus 5.5 months for the comparator combination. Roche indicated a monthly price of approximately $22,500 and expects U.S. availability within weeks. The company is also pursuing an earlier-stage breast cancer indication, which could represent a substantially larger commercial opportunity.

Reuters

Reuters · November 16, 2026

Why it matters strategically

This approval changes the competitive landscape for endocrine-resistant breast cancer and creates immediate questions about sequencing, differentiation, reimbursement, and licensing valuations.

The 62% relative reduction in progression or death is clinically important, but it does not establish a comparable overall survival benefit or superiority over therapies evaluated in separate trials.

Previous
Previous

Eli Lilly Agrees to Acquire Calytrix for Up to $1.5 Billion Before Human Clinical Trials

Next
Next

U.S. Diesel Prices Fall Below $6 as Energy Costs Begin to Ease